Skip to content
Peptide research

Selank

Also known as TP-7 · Selanc
Category
Brain & Cognition
Administration routes
Nasal
Regulatory status
Not FDA-approved

What it is

A synthetic, stabilized analog of the immune peptide tuftsin, used intranasally mainly for anxiety, focus, and immunity. Its anxiolytic and anti-inflammatory effects have the most support, but human trials are almost all Russian, small, and short (7 to 21 days). The FDA has flagged immunogenicity, with no pregnancy, lactation, or pediatric data. Not an approved US drug, and most supply outside Russia is unregulated research-grade material.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Anxiolytic effects comparable to benzodiazepines without their side effects

    Medium

    Small human trials found anxiety relief comparable to benzodiazepines, without sedation or dependence.

  • Neuroprotection and cognitive enhancement via BDNF elevation

    Low

    The cited rat study found preserved memory and prevention of an ethanol-induced BDNF increase; human cognitive benefit remains unestablished.

  • Anti-inflammatory and immunomodulatory effects

    Medium

    A human study showed shifted cytokine levels; clinical anti-inflammatory benefit remains unproven.

Evidence limits

Evidence Level
Moderate

Selank's clinical evidence base is moderate but geographically concentrated. The primary human evidence comes from Russian clinical trials: an RCT in 62 GAD/neurasthenia patients showing anxiolytic efficacy comparable to medazepam without benzodiazepine side effects (Zozulia et al. 2008); a clinical evaluation in 20 GAD patients identifying rapid and slow responder subtypes with significant HARS score reductions (Syunyakov et al. 2012); and immunomodulatory effects documented in anxiety patients showing IL-6 suppression and Th1/Th2 rebalancing (Uchakina et al. 2008). Preclinical evidence is substantially more extensive, with well-designed studies demonstrating BDNF elevation, GABAergic gene modulation, anti-inflammatory cytokine regulation, neuroprotection against ethanol-induced cognitive impairment, and attenuation of opioid withdrawal. The major gaps are the absence of large international RCTs replicating the Russian clinical findings, no long-term safety studies beyond 14-21 day treatment courses, and no clinical trials specifically targeting aging or longevity outcomes.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Severe hypotension

    Moderate

    Selank's anxiolytic effects may further lower blood pressure.

General cautions

  • Pregnancy

    Absolute

    No reproductive safety data outside Russia.

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Most clinical studies examine only 7-21 day treatment periods

    Moderate
  • FDA cited immunogenicity as a safety concern

    Moderate
  • Mild nasal or throat irritation (intranasal)

    Low
  • Rare mild dizziness

    Low
  • No safety data in pregnancy, lactation, or children

    Moderate
  • Mostly research-grade outside Russia/Ukraine

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.